Augmented animals exhibited high rates of survival (Group 1: 5/6, 83%; Group 2: 4/4, 100%) and voluntary voiding over the course of the study period.
Plasma miR-26a and miR-27a levels showed significantly different between non-survival group and survival group in ARDSp patients.
Plasma miR-26a and miR-27a levels in non-survival group are significantly lower than that in survival group in ARDSp patients.
The perfused small vessel density and proportion of perfused vessels at 24 h were higher in the Survival group than in the Non-survival group.
In addition, we found plasma miR-26a and miR-27a levels in non-survival group exhibited significantly lower than that in survival group in ARDSp patients.
In our univariate analysis, there were more patients without preexisting comorbidities in the survival group than in the non-survival group.
Conclusions: Our results revealed that the perfused small vessel density were higher in the Survival group than in the Non-survival group.
The endocan level were higher in the Non-survival group than in the Survival group, but the difference was not significant.
Fig. 4 Comparison of MSC-VEC-miRNAs between survival group and death group in ARDSp patients.
After stratification by mean central venous pressure, elevated duration of central venous pressure above 10 mmHg was significantly higher in the non-survival group than in the survival group.
After stratification by different levels of mean CVP, as in Additional file 1: Supplement Figure 2, the results showed that the ECVP10 duration in non-survival group was significantly higher than in the survival group.
